Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in French pharma major Sanofi's strategy. Sanofi announced today the closing of the sale to US private ...

The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q2Stay Ahead of the Market: Discover outperforming ...

Sanofi confirms the expectation of a strong ... the upcoming closing of the sale of a majority stake in Opella and the recent acquisition of a bispecific myeloid cell engager for deep B-cell ...

The brand tries to answer a question: can we follow the 5-second rule to eat food after it falls on the floor? SÃO PAULO, ...

In October 2023, Sanofi announced its intention to separate its Consumer Healthcare (CHC) unit through the creation of a publicly listed entity headquartered in Paris to be called Opella.

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling ...